UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2018

(Commission File No.  001-38217 )

 

Nightstar Therapeutics plc

(Translation of registrant’s name into English)

 

215 Euston Road

London NW1 2BE United Kingdom

(Address of registrant’s principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F   ☒ Form 40-F   ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1): __

    

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7): __

    

 

 

 

EXHIBIT INDEX

 

 

1

 

SIGNAT URES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

 

 

 

 

NIGHTSTAR THERAPEUTICS PLC

 

 

 

By:

 

/s/ David Fellows

Name:

 

David Fellows

Title:

 

Chief Executive Officer

 

 

 

Date: June 13, 2018

 

 

2

Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Nightstar Therapeutics Plc ADS Charts.
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Nightstar Therapeutics Plc ADS Charts.